- Home
- BANC vs AKRO Comparison
BANC vs AKRO Comparison
Compare BANC & AKRO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | BANC | AKRO |
|---|---|---|
| Founded | 1941 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 2.9B | 4.5B |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | BANC | AKRO |
|---|---|---|
| Price | $19.67 | $54.65 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 9 | 11 |
| Target Price | $19.61 | ★ $73.56 |
| AVG Volume (30 Days) | 2.0M | ★ 2.4M |
| Earning Date | 01-22-2026 | 11-07-2025 |
| Dividend Yield | ★ 2.02% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 1.03 | N/A |
| Revenue | ★ $1,019,965,000.00 | N/A |
| Revenue This Year | $4.33 | N/A |
| Revenue Next Year | $14.27 | N/A |
| P/E Ratio | $19.23 | ★ N/A |
| Revenue Growth | ★ 147.22 | N/A |
| 52 Week Low | $11.52 | $21.34 |
| 52 Week High | $20.17 | $58.40 |
Technical Indicators
Market Signals| Indicator | BANC | AKRO |
|---|---|---|
| Relative Strength Index (RSI) | 68.30 | 68.63 |
| Support Level | $19.51 | $54.30 |
| Resistance Level | $20.07 | $54.70 |
| Average True Range (ATR) | 0.40 | 0.17 |
| MACD | 0.00 | -0.10 |
| Stochastic Oscillator | 68.79 | 71.07 |
Price Performance
Historical ComparisonAbout BANC Banc of California Inc.
Banc of California Inc is a financial holding company. It offers banking and financial services. Its services include banking services, lending services, and private banking services. Its deposit and banking product and service offerings include checking, savings, money market, certificates of deposit, and retirement accounts. Lending activities are focused on providing financing to California's diverse private businesses, entrepreneurs, and communities, and loans are often secured by California commercial and residential real estate. The company has one reportable segment named Commercial banking.
About AKRO Akero Therapeutics Inc.
Akero Therapeutics Inc is a clinical-stage biotechnology company focused on developing and commercializing transformative treatments for serious metabolic diseases with high unmet medical needs. Its focus is nonalcoholic steatohepatitis (MASH), or NASH, a disease without any approved therapies. The company's product candidate efruxifermin is an FGF21 analog with properties that have the potential to address the core processes underlying NASH pathogenesis.